Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis.
Mol Cells
; 44(6): 392-400, 2021 Jun 30.
Article
in English
| MEDLINE | ID: covidwho-1249738
ABSTRACT
It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humoral immunity to SARS-CoV-2 has been studied extensively, though there is still much that is unknown and controversial. Here, we introduce key discoveries on the humoral immune responses in COVID-19, including the immune dynamics of antibody responses and correlations with disease severity, neutralizing antibodies and their cross-reactivity, how long the antibody and memory B-cell responses last, aberrant autoreactive antibodies generated in COVID-19 patients, and the efficacy of currently available therapeutic antibodies and vaccines against circulating SARS-CoV-2 variants, and highlight gaps in the current knowledge.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunoglobulin G
/
B-Lymphocytes
/
Immunoglobulin Class Switching
/
Antibodies, Neutralizing
/
SARS-CoV-2
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
/
Variants
Limits:
Humans
Language:
English
Journal:
Mol Cells
Journal subject:
Molecular Biology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS